The Gut Punch
@thegutpunch.com
Hard-Hitting Insights on the War on Obesity and the Food Industrial Complex.
Pinned
The Gut Punch
@thegutpunch.com
· Feb 6
NEW: Our investigation reveals how America's broken healthcare system is compromising GLP-1 treatment outcomes.
With 80% of patients forced to discontinue within 2 years, emerging evidence suggests current practices may leave patients metabolically worse than before.
With 80% of patients forced to discontinue within 2 years, emerging evidence suggests current practices may leave patients metabolically worse than before.
Wegovy just got FDA approval to treat MASH (liver disease)—a huge step beyond weight loss. It’s also cleared for sale in China. Novo Nordisk is pushing ahead with new drugs like CagriSema and amycretin—watch this space for more breakthroughs.
September 22, 2025 at 3:38 PM
Wegovy just got FDA approval to treat MASH (liver disease)—a huge step beyond weight loss. It’s also cleared for sale in China. Novo Nordisk is pushing ahead with new drugs like CagriSema and amycretin—watch this space for more breakthroughs.
Teva just launched the first generic Saxenda for obesity in the US—priced at $1,165/month vs. $1,350 for branded. But with Ozempic & Wegovy surging in popularity and compounded meds on the rise, will generics make a real impact?
September 18, 2025 at 3:38 PM
Teva just launched the first generic Saxenda for obesity in the US—priced at $1,165/month vs. $1,350 for branded. But with Ozempic & Wegovy surging in popularity and compounded meds on the rise, will generics make a real impact?
A new real-world study shows Wegovy beats Zepbound in lowering heart attack, stroke & death risk for obese patients with heart disease. Wegovy cut risk by 57% (consistent use) vs. Zepbound & by 29% overall. Zepbound leads on weight loss but lacks CV approval.
September 16, 2025 at 3:38 PM
A new real-world study shows Wegovy beats Zepbound in lowering heart attack, stroke & death risk for obese patients with heart disease. Wegovy cut risk by 57% (consistent use) vs. Zepbound & by 29% overall. Zepbound leads on weight loss but lacks CV approval.
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐁𝐈-𝐖𝐄𝐄𝐊𝐋𝐘 #31
Wegovy beats Zepbound for heart health—a real-world study found 57% lower risk! Teva launches first generic Saxenda. Wegovy wins new liver disease approval + expands to China. CVS sued over dropping Zepbound from coverage.
Wegovy beats Zepbound for heart health—a real-world study found 57% lower risk! Teva launches first generic Saxenda. Wegovy wins new liver disease approval + expands to China. CVS sued over dropping Zepbound from coverage.
September 10, 2025 at 3:38 PM
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐁𝐈-𝐖𝐄𝐄𝐊𝐋𝐘 #31
Wegovy beats Zepbound for heart health—a real-world study found 57% lower risk! Teva launches first generic Saxenda. Wegovy wins new liver disease approval + expands to China. CVS sued over dropping Zepbound from coverage.
Wegovy beats Zepbound for heart health—a real-world study found 57% lower risk! Teva launches first generic Saxenda. Wegovy wins new liver disease approval + expands to China. CVS sued over dropping Zepbound from coverage.
GLP-1 drugs for diabetes & weight loss linked to a 17% lower overall cancer risk (10-year study, 86k+ people).
Endometrial: -25%
Ovarian: -47%
Meningioma: -31%
Slight (not significant) uptick in kidney cancer observed.
Endometrial: -25%
Ovarian: -47%
Meningioma: -31%
Slight (not significant) uptick in kidney cancer observed.
September 4, 2025 at 3:43 PM
GLP-1 drugs for diabetes & weight loss linked to a 17% lower overall cancer risk (10-year study, 86k+ people).
Endometrial: -25%
Ovarian: -47%
Meningioma: -31%
Slight (not significant) uptick in kidney cancer observed.
Endometrial: -25%
Ovarian: -47%
Meningioma: -31%
Slight (not significant) uptick in kidney cancer observed.
Universal access to GLP-1 drugs like Ozempic could save billions in U.S. healthcare costs by preventing obesity, diabetes & heart disease. If prices fall with bulk buying, benefits may outweigh costs—a smart investment in national health.
September 2, 2025 at 3:38 PM
Universal access to GLP-1 drugs like Ozempic could save billions in U.S. healthcare costs by preventing obesity, diabetes & heart disease. If prices fall with bulk buying, benefits may outweigh costs—a smart investment in national health.
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐁𝐈-𝐖𝐄𝐄𝐊𝐋𝐘 #30
💸 Universal access to Ozempic/GLP-1s could save billions on US healthcare costs
🛡️ Study: Users have 17% lower cancer risk
💊 Lilly’s oral pill nears FDA approval with strong results
🌱 New plant beads trap dietary fat—no meds needed
💸 Universal access to Ozempic/GLP-1s could save billions on US healthcare costs
🛡️ Study: Users have 17% lower cancer risk
💊 Lilly’s oral pill nears FDA approval with strong results
🌱 New plant beads trap dietary fat—no meds needed
August 27, 2025 at 3:38 PM
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐁𝐈-𝐖𝐄𝐄𝐊𝐋𝐘 #30
💸 Universal access to Ozempic/GLP-1s could save billions on US healthcare costs
🛡️ Study: Users have 17% lower cancer risk
💊 Lilly’s oral pill nears FDA approval with strong results
🌱 New plant beads trap dietary fat—no meds needed
💸 Universal access to Ozempic/GLP-1s could save billions on US healthcare costs
🛡️ Study: Users have 17% lower cancer risk
💊 Lilly’s oral pill nears FDA approval with strong results
🌱 New plant beads trap dietary fat—no meds needed
Lilly’s new oral GLP-1 pill helped people lose 12% of their body weight in trials (avg. 27 lbs in 72 weeks). It’s easier than injections—but not as powerful as Wegovy or Zepbound.
Would you swap shots for a daily pill?
Would you swap shots for a daily pill?
August 25, 2025 at 3:38 PM
Lilly’s new oral GLP-1 pill helped people lose 12% of their body weight in trials (avg. 27 lbs in 72 weeks). It’s easier than injections—but not as powerful as Wegovy or Zepbound.
Would you swap shots for a daily pill?
Would you swap shots for a daily pill?
Ozempic made Novo Nordisk a star—but supply issues & slow innovation have let competitors (like Eli Lilly) take the lead. Analysts downgrade the stock amid doubts about market size & rising pricing pressure. Is their dominance fading?
August 21, 2025 at 3:38 PM
Ozempic made Novo Nordisk a star—but supply issues & slow innovation have let competitors (like Eli Lilly) take the lead. Analysts downgrade the stock amid doubts about market size & rising pricing pressure. Is their dominance fading?
The Trump admin is eyeing a 5-year trial to let Medicare & Medicaid cover GLP-1 weight loss drugs as early as 2026. Only 13 states currently offer such coverage via Medicaid. HHS calls them “miracle drugs,” but says they should go hand-in-hand with exercise.
August 14, 2025 at 3:38 PM
The Trump admin is eyeing a 5-year trial to let Medicare & Medicaid cover GLP-1 weight loss drugs as early as 2026. Only 13 states currently offer such coverage via Medicaid. HHS calls them “miracle drugs,” but says they should go hand-in-hand with exercise.
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐁𝐈-𝐖𝐄𝐄𝐊𝐋𝐘 #29
💊 Medicare may trial covering obesity drugs by 2026
📉 Ozempic faces supply woes & copycats; Novo downgraded
💪 Lilly's oral weight-loss pill shows 12% drop—less than injectables
💊 Medicare may trial covering obesity drugs by 2026
📉 Ozempic faces supply woes & copycats; Novo downgraded
💪 Lilly's oral weight-loss pill shows 12% drop—less than injectables
August 13, 2025 at 3:38 PM
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐁𝐈-𝐖𝐄𝐄𝐊𝐋𝐘 #29
💊 Medicare may trial covering obesity drugs by 2026
📉 Ozempic faces supply woes & copycats; Novo downgraded
💪 Lilly's oral weight-loss pill shows 12% drop—less than injectables
💊 Medicare may trial covering obesity drugs by 2026
📉 Ozempic faces supply woes & copycats; Novo downgraded
💪 Lilly's oral weight-loss pill shows 12% drop—less than injectables
Trump’s new 15% tariff on European drugs could push up prices for Americans. Europe supplies nearly half the ingredients in U.S. brand-name meds. Expect drugmakers to pass costs onto patients—higher out-of-pocket bills and insurance premiums may follow.
August 5, 2025 at 3:38 PM
Trump’s new 15% tariff on European drugs could push up prices for Americans. Europe supplies nearly half the ingredients in U.S. brand-name meds. Expect drugmakers to pass costs onto patients—higher out-of-pocket bills and insurance premiums may follow.
Novo Nordisk’s stock plunged over 20%, hitting a three-year low after slashing its sales growth forecast for 2025. Tough U.S. competition from rival GLP-1s & compounded drugs is taking a toll. New CEO Mike Doustdar steps in as pressure mounts from investors to stop the bleeding.
August 4, 2025 at 3:38 PM
Novo Nordisk’s stock plunged over 20%, hitting a three-year low after slashing its sales growth forecast for 2025. Tough U.S. competition from rival GLP-1s & compounded drugs is taking a toll. New CEO Mike Doustdar steps in as pressure mounts from investors to stop the bleeding.
GLP-1 drugs like Ozempic might be more than weight-loss meds—they could cut risks for Alzheimer’s, addiction & infections too. A huge VA study found users had up to 20% lower risk for dozens of conditions. But at $1K+/month—who’ll have access?
July 31, 2025 at 3:38 PM
GLP-1 drugs like Ozempic might be more than weight-loss meds—they could cut risks for Alzheimer’s, addiction & infections too. A huge VA study found users had up to 20% lower risk for dozens of conditions. But at $1K+/month—who’ll have access?
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐖𝐄𝐄𝐊𝐋𝐘 #28
GLP-1s like Ozempic show benefits way beyond weight loss, including lower Alzheimer’s risk — but high costs limit access. Novo stock drops 20% amid stiff competition & profit warning. Trump imposes new EU drug tariffs — Rx prices may rise.
GLP-1s like Ozempic show benefits way beyond weight loss, including lower Alzheimer’s risk — but high costs limit access. Novo stock drops 20% amid stiff competition & profit warning. Trump imposes new EU drug tariffs — Rx prices may rise.
July 30, 2025 at 3:38 PM
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐖𝐄𝐄𝐊𝐋𝐘 #28
GLP-1s like Ozempic show benefits way beyond weight loss, including lower Alzheimer’s risk — but high costs limit access. Novo stock drops 20% amid stiff competition & profit warning. Trump imposes new EU drug tariffs — Rx prices may rise.
GLP-1s like Ozempic show benefits way beyond weight loss, including lower Alzheimer’s risk — but high costs limit access. Novo stock drops 20% amid stiff competition & profit warning. Trump imposes new EU drug tariffs — Rx prices may rise.
Hims & Hers Health is leading the charge in knockoff GLP-1 weight-loss drugs. With rapid growth fueled by demand for affordable alternatives—and a CEO who microdoses and uses AI advice—Hims is shaking up pharma's hold on obesity meds.
July 22, 2025 at 3:38 PM
Hims & Hers Health is leading the charge in knockoff GLP-1 weight-loss drugs. With rapid growth fueled by demand for affordable alternatives—and a CEO who microdoses and uses AI advice—Hims is shaking up pharma's hold on obesity meds.
Ozempic isn’t just for weight loss—Caron Treatment Centers is trialing it off-label to curb addiction cravings. Early reports show striking success, but it remains experimental outside elite rehab settings.
July 21, 2025 at 3:38 PM
Ozempic isn’t just for weight loss—Caron Treatment Centers is trialing it off-label to curb addiction cravings. Early reports show striking success, but it remains experimental outside elite rehab settings.
Hengrui's new GLP-1/GIP drug hit nearly 18% weight loss at 48 weeks—matching Zepbound—in phase 3 trials with mostly mild GI side effects. Approval could bring another homegrown option to China soon. Global studies for higher doses are next.
July 19, 2025 at 3:38 PM
Hengrui's new GLP-1/GIP drug hit nearly 18% weight loss at 48 weeks—matching Zepbound—in phase 3 trials with mostly mild GI side effects. Approval could bring another homegrown option to China soon. Global studies for higher doses are next.
Kate Farms launches a high-protein plant-based shake made for GLP-1 users! Each dairy-free shake packs 25g protein, 6g fiber & zero sugar -- clinically-developed to support muscle health during weight loss.
July 18, 2025 at 3:38 PM
Kate Farms launches a high-protein plant-based shake made for GLP-1 users! Each dairy-free shake packs 25g protein, 6g fiber & zero sugar -- clinically-developed to support muscle health during weight loss.
Not all protein is created equal! Most brands chase hype over quality—but millions of GLP-1 users need high-digestibility, nutrient-dense options in small portions. The real opportunity? Clinical-grade proteins designed for real results. Who'll seize it first?
July 17, 2025 at 3:38 PM
Not all protein is created equal! Most brands chase hype over quality—but millions of GLP-1 users need high-digestibility, nutrient-dense options in small portions. The real opportunity? Clinical-grade proteins designed for real results. Who'll seize it first?
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐖𝐄𝐄𝐊𝐋𝐘 #27
Brands add protein to everything while real nutritional needs - especially for GLP-1 users - are ignored. Is this innovation or just marketing hype?
Plus:
1️⃣ Ozempic used off-label for addiction
2️⃣ Hengrui's new obesity drug
3️⃣ Hims rules generics
Brands add protein to everything while real nutritional needs - especially for GLP-1 users - are ignored. Is this innovation or just marketing hype?
Plus:
1️⃣ Ozempic used off-label for addiction
2️⃣ Hengrui's new obesity drug
3️⃣ Hims rules generics
July 16, 2025 at 3:38 PM
🥊 𝐓𝐇𝐄 𝐆𝐔𝐓 𝐏𝐔𝐍𝐂𝐇 𝐖𝐄𝐄𝐊𝐋𝐘 #27
Brands add protein to everything while real nutritional needs - especially for GLP-1 users - are ignored. Is this innovation or just marketing hype?
Plus:
1️⃣ Ozempic used off-label for addiction
2️⃣ Hengrui's new obesity drug
3️⃣ Hims rules generics
Brands add protein to everything while real nutritional needs - especially for GLP-1 users - are ignored. Is this innovation or just marketing hype?
Plus:
1️⃣ Ozempic used off-label for addiction
2️⃣ Hengrui's new obesity drug
3️⃣ Hims rules generics
More people are sticking with weight-loss drugs: now 63% stay on Wegovy or Zepbound for a year (up from 40%). But only 14% remain after three years. Is long-term use sustainable—or even necessary—to keep the weight off?
July 8, 2025 at 3:38 PM
More people are sticking with weight-loss drugs: now 63% stay on Wegovy or Zepbound for a year (up from 40%). But only 14% remain after three years. Is long-term use sustainable—or even necessary—to keep the weight off?
China approves mazdutide—the world’s first dual GLP-1/glucagon drug—for chronic weight management. In trials: nearly 15% average weight loss at 48 weeks! A big step for incretin therapies as China tackles its growing obesity crisis.
July 7, 2025 at 3:38 PM
China approves mazdutide—the world’s first dual GLP-1/glucagon drug—for chronic weight management. In trials: nearly 15% average weight loss at 48 weeks! A big step for incretin therapies as China tackles its growing obesity crisis.
Novo Nordisk just pulled Wegovy from Hims & Hers after accusing them of selling unsafe compounded GLP-1s and misleading patients. Stock dropped 30%. Hims’ CEO denied wrongdoing and says they’ll still offer weight loss options—including Wegovy—for patients.
July 4, 2025 at 3:38 PM
Novo Nordisk just pulled Wegovy from Hims & Hers after accusing them of selling unsafe compounded GLP-1s and misleading patients. Stock dropped 30%. Hims’ CEO denied wrongdoing and says they’ll still offer weight loss options—including Wegovy—for patients.
Lilly’s new antibody bimagrumab + Wegovy delivers big fat loss AND preserves muscle—22.1% total weight loss with nearly all from fat! Some safety concerns (liver/pancreatic enzymes) remain.
July 3, 2025 at 3:38 PM
Lilly’s new antibody bimagrumab + Wegovy delivers big fat loss AND preserves muscle—22.1% total weight loss with nearly all from fat! Some safety concerns (liver/pancreatic enzymes) remain.